Report cover image

Complicated Intra-Abdominal Infections - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 50 Pages
SKU # DEL18679418

Description

Complicated Intra-Abdominal Infections - Pipeline Insight, 2024



DelveInsight’s, “Complicated Intra-Abdominal Infections – Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Complicated Intra-Abdominal Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Complicated Intra-Abdominal Infections Understanding

Complicated Intra-Abdominal Infections: Overview

Complicated intra-abdominal infections (cIAI) are the infections that extend beyond the source organ into the peritoneal space as a result of perforation or other damage to the gastrointestinal tract. The disease is associated with either abscess formation or peritonitis. This type of infection is usually polymicrobial and is caused by Gram-negative aerobic bacteria, Gram-positive bacteria and anaerobic bacteria.

Symptoms

The symptoms of Complicated Intra-Abdominal Infections include:
  • Fever
  • Tachycardia
  • Hypotension
  • Abdominal pain and Abdominal fullness
  • Nausea and vomiting
  • Diarrhea
  • Obstipation
  • Acidosis
Diagnosis

Complicated intra-abdominal infections (cIAI) diagnoses include intra-abdominal abscess, stomach or intestinal perforation, peritonitis, appendicitis, cholecystitis or diverticulitis along with physical assessment findings. Serum lactic acid, arterial blood gases, and oxygen saturation levels are usually tested, especially if sepsis is suspected. Moreover, radiographic images using CT scans with oral and intravenous contrast can also be useful for visualization of the abdominal cavity.

Treatment

Complicated intra-abdominal infections (cIAI) can be treated with early detection, containment and appropriate antimicrobial treatment. Treatment is based on the severity of infection and whether the infection is community- or healthcare-acquired. There is a wide range of antimicrobial agents and combinations of agents available for use in complicated intra-abdominal infection. The widely used antimicrobial treatments are the combination of cefotaxime or ceftriaxone with metronidazole and monotherapy with amoxicillin/clavulanic acid. Because of widespread resistance of E. coli to ampicillin-sulbactam, this is no longer recommended for routine empiric therapy of complicated intra-abdominal infection. Increasing rates of infections caused by drug-resistant bacteria limit the effectiveness of currently available antibiotics.

Complicated Intra-Abdominal Infections Emerging Drugs Chapters

This segment of the Complicated Intra-Abdominal Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Complicated Intra-Abdominal Infections Emerging Drugs
  • Sulopenem: Interim Therapeutics
Sulopenem is a novel agent that has demonstrated in vitro activity against gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Sulopenem is being evaluated in phase 3 clinical trials for complicated intra-abdominal infections. The USFDA has granted Special Protocol Agreements and Qualified Infectious Disease Product designations for Sulopenem.
  • Avibactam/aztreonam: AbbVie
Aztreonam / Avibactam is a combination being investigated for treatment of complicated gram-negative bacterial infections. In the combination, Avibactam inhibits the serine-β-lactamases and allows Aztreonam to work against MBL-producing pathogens. In November 2019, The Food and Drug Administration has granted Qualified Infectious Disease Product (QIDP) designation and Fast Track designation to Aztreonam/Avibactam for the treatment of complicated intra-abdominal infections.

Further product details are provided in the report……..

Complicated Intra-Abdominal Infections: Therapeutic Assessment

This segment of the report provides insights about the different Complicated Intra-Abdominal Infections drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in Complicated Intra-Abdominal Infections
There are approx. 15+ key companies which are developing the therapies for Complicated Intra-Abdominal Infections. The companies which have their Complicated Intra-Abdominal Infections drug candidates in the most advanced stage, i.e. phase III include, AbbVie.
  • Phases
DelveInsight’s report covers around 15+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Complicated Intra-Abdominal Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Complicated Intra-Abdominal Infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Complicated Intra-Abdominal Infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Complicated Intra-Abdominal Infections drugs.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Complicated Intra-Abdominal Infections R&D. The therapies under development are focused on novel approaches to treat/improve Complicated Intra-Abdominal Infections.
  • In July 2019, Nosopharm and Evotec announced their partnership aiming at advancing Nosopharm’s lead candidate, NOSO-502, to the clinical stage, as well as developing a second-generation Odilorhabdin drug candidate.
Complicated Intra-Abdominal Infections Report Insights
  • Complicated Intra-Abdominal Infections Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Complicated Intra-Abdominal Infections Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Complicated Intra-Abdominal Infections drugs?
  • How many Complicated Intra-Abdominal Infections drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Complicated Intra-Abdominal Infections?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Complicated Intra-Abdominal Infections therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Complicated Intra-Abdominal Infections and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • MerLion Pharmaceuticals
  • AiCuris
  • Novartis
  • Allecra
  • AbbVie
  • AstraZeneca
  • Pfizer
  • Shionogi
  • Iterum Therapeutics
  • Nosopharm
Key Products
  • Finafloxacin
  • AIC499
  • LYS-228
  • Cefepime/AAI101
  • Avibactam/aztreonam
  • Cefiderocol
  • Sulopenem etzadroxil
  • NOSO-502

Table of Contents

50 Pages
Introduction
Executive Summary
Complicated Intra-Abdominal Infections: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Complicated Intra-Abdominal Infections – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Complicated Intra-Abdominal Infections companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Complicated Intra-Abdominal Infections Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Avibactam/aztreonam: AbbVie
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Finafloxacin - MerLion Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Complicated Intra-Abdominal Infections Key Companies
Complicated Intra-Abdominal Infections Key Products
Complicated Intra-Abdominal Infections- Unmet Needs
Complicated Intra-Abdominal Infections- Market Drivers and Barriers
Complicated Intra-Abdominal Infections- Future Perspectives and Conclusion
Complicated Intra-Abdominal Infections Analyst Views
Complicated Intra-Abdominal Infections Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us